The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

Condition:   Antineutrophil Cytoplasmic Antibody Associated Vasculitis Intervention:   Drug: STSA-1002 subcutaneous injection Sponsor:   Staidson (Beijing) Biopharmaceuticals Co., Ltd Not yet recruiting

Source: ClinicalTrials.gov - January 27, 2023 Category: Research Source Type: clinical trials